Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M||cholangiocarcinoma||predicted - resistant||Infigratinib||Case Reports/Case Series||Actionable||In a Phase II trial, a patient with cholangiocarcinoma harboring FGFR2-SHTN1 initially responded to treatment with Infigratinib (BGJ398), but progressed after eight months and via repeat tissue biopsy was found to have acquired FGFR2 E565A, and via circulating tumor DNA testing, FGFR2 L617M (PMID: 31911531).||31911531|
|FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M||Advanced Solid Tumor||sensitive||Infigratinib + Sapanisertib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with Infigratinib (BGJ398), demonstrating synergistic effects (PMID: 31911531).||31911531|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|